Anna Offersgaard

693 total citations · 1 hit paper
18 papers, 406 citations indexed

About

Anna Offersgaard is a scholar working on Infectious Diseases, Hepatology and Epidemiology. According to data from OpenAlex, Anna Offersgaard has authored 18 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 9 papers in Hepatology and 8 papers in Epidemiology. Recurrent topics in Anna Offersgaard's work include SARS-CoV-2 and COVID-19 Research (9 papers), Hepatitis C virus research (9 papers) and Hepatitis B Virus Studies (8 papers). Anna Offersgaard is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (9 papers), Hepatitis C virus research (9 papers) and Hepatitis B Virus Studies (8 papers). Anna Offersgaard collaborates with scholars based in Denmark, Germany and United States. Anna Offersgaard's co-authors include Jens Bukh, Judith M. Gottwein, Ulrik Fahnøe, Santseharay Ramírez, Karen Anbro Gammeltoft, Yuyong Zhou, Long V. Pham, Shan Feng, Line A. Ryberg and Alekxander Binderup and has published in prestigious journals such as Science, Hepatology and Gut.

In The Last Decade

Anna Offersgaard

17 papers receiving 402 citations

Hit Papers

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitn... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
    2022 132 citations Yuyong Zhou, Karen Anbro Gammeltoft et al. Science Advances profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Offersgaard Denmark 11 226 97 94 85 74 18 406
Long V. Pham Denmark 13 309 1.4× 106 1.1× 141 1.5× 185 2.2× 188 2.5× 23 614
Soonju Park South Korea 8 377 1.7× 116 1.2× 121 1.3× 102 1.2× 50 0.7× 10 573
Gitanjali Subramanya United States 7 438 1.9× 62 0.6× 114 1.2× 231 2.7× 166 2.2× 8 793
Carlota Fernandez-Antunez Denmark 10 279 1.2× 68 0.7× 75 0.8× 51 0.6× 28 0.4× 17 341
Daniel Brian Nichols United States 12 339 1.5× 129 1.3× 214 2.3× 130 1.5× 57 0.8× 18 701
Tianhong Zhang China 12 174 0.8× 49 0.5× 159 1.7× 80 0.9× 12 0.2× 13 420
Carina Elsner Germany 11 201 0.9× 37 0.4× 107 1.1× 91 1.1× 70 0.9× 21 510
G.J. Lockbaum United States 13 250 1.1× 167 1.7× 164 1.7× 62 0.7× 31 0.4× 21 448
Emma Woolner Canada 4 682 3.0× 135 1.4× 207 2.2× 72 0.8× 16 0.2× 6 847
Thi-Tuyet-Nhung Le France 7 610 2.7× 112 1.2× 254 2.7× 89 1.0× 22 0.3× 14 811

Countries citing papers authored by Anna Offersgaard

Since Specialization
Citations

This map shows the geographic impact of Anna Offersgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Offersgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Offersgaard more than expected).

Fields of papers citing papers by Anna Offersgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Offersgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Offersgaard. The network helps show where Anna Offersgaard may publish in the future.

Co-authorship network of co-authors of Anna Offersgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Offersgaard. A scholar is included among the top collaborators of Anna Offersgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Offersgaard. Anna Offersgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zhou, Yuyong, Karen Anbro Gammeltoft, Line A. Ryberg, et al.. (2025). SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots. Emerging Microbes & Infections. 14(1). 2552716–2552716.
2.
Offersgaard, Anna, Yuyong Zhou, Z. H. Duan, et al.. (2024). An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals. Scientific Reports. 14(1). 17039–17039. 1 indexed citations
3.
Gammeltoft, Karen Anbro, Yuyong Zhou, Line A. Ryberg, et al.. (2023). Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Viruses. 15(9). 1970–1970. 10 indexed citations
4.
Offersgaard, Anna, Shan Feng, Pavel Marichal‐Gallardo, et al.. (2023). An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience. 26(2). 105949–105949. 5 indexed citations
5.
Offersgaard, Anna, Jens Bukh, & Judith M. Gottwein. (2023). Toward a vaccine against hepatitis C virus. Science. 380(6640). 37–38. 15 indexed citations
6.
Offersgaard, Anna, Ania M. Owsianka, Jens Bukh, et al.. (2023). Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles. Microbiology Spectrum. 11(2). e0254622–e0254622. 3 indexed citations
7.
Zhou, Yuyong, Karen Anbro Gammeltoft, Line A. Ryberg, et al.. (2022). Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Science Advances. 8(51). eadd7197–eadd7197. 132 indexed citations breakdown →
8.
Feng, Shan, Anna Offersgaard, Tanja B. Jensen, et al.. (2022). Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. Journal of Hepatology. 76(5). 1051–1061. 16 indexed citations
9.
Offersgaard, Anna, Rodrigo Velázquez‐Moctezuma, Ulrik Fahnøe, et al.. (2022). Identification of novel neutralizing determinants for protection against HCV. Hepatology. 77(3). 982–996. 6 indexed citations
10.
Offersgaard, Anna, Nandini Venkatesan, Henrik Krarup, et al.. (2022). High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines. 10(2). 249–249. 4 indexed citations
11.
Offersgaard, Anna, Z. H. Duan, Shan Feng, et al.. (2022). Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. Gut. 72(3). 560–572. 13 indexed citations
12.
Zhou, Yuyong, Karen Anbro Gammeltoft, Andrea Galli, et al.. (2021). Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. Viruses. 13(10). 2082–2082. 24 indexed citations
13.
Gammeltoft, Karen Anbro, Yuyong Zhou, Andrea Galli, et al.. (2021). Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrobial Agents and Chemotherapy. 65(9). e0268020–e0268020. 37 indexed citations
14.
Zhou, Yuyong, Kerry Gilmore, Santseharay Ramírez, et al.. (2021). In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. Scientific Reports. 11(1). 14571–14571. 70 indexed citations
15.
Offersgaard, Anna, Rui Costa, Nandini Venkatesan, et al.. (2021). SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. Vaccines. 9(7). 706–706. 15 indexed citations
16.
Offersgaard, Anna, Tanja B. Jensen, Ulrik Fahnøe, et al.. (2020). Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Scientific Reports. 10(1). 16261–16261. 25 indexed citations
17.
18.
Offersgaard, Anna, Jannick Prentoe, Ulrik Fahnøe, et al.. (2018). High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Scientific Reports. 8(1). 17505–17505. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Long V. Pham Breakdown of academic impact, for papers by Soonju Park Breakdown of academic impact, for papers by Gitanjali Subramanya Breakdown of academic impact, for papers by Carlota Fernandez-Antunez Breakdown of academic impact, for papers by Daniel Brian Nichols Breakdown of academic impact, for papers by Tianhong Zhang Breakdown of academic impact, for papers by Carina Elsner Breakdown of academic impact, for papers by G.J. Lockbaum Breakdown of academic impact, for papers by Emma Woolner Breakdown of academic impact, for papers by Thi-Tuyet-Nhung Le
Rankless by CCL
2026